Maria Adelaide Caligo

List of Publications by Year
in descending order

158 papers	8,496 citations	53660 45 h-index	54797 84 g-index
166 all docs	166 docs citations	166 times ranked	10882 citing authors

#	Article	IF	Citations
1	Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147.	1.1	513
2	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	3.8	390
3	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
4	Multicenter Comparative Multimodality Surveillance of Women at Genetic-Familial High Risk for Breast Cancer (HIBCRIT Study): Interim Results. Radiology, 2007, 242, 698-715.	3.6	324
5	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptorâ€“negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892.	9.4	309
6	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
7	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	9.4	265
8	Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. American Journal of Human Genetics, 2008, 82, 937-948.	2.6	257
9	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	1.5	244
10	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, .	3.0	242
11	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	1.1	224
12	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
13	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. Cancer Research, 2010, 70, 9742-9754.	0.4	169
14	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	0.8	152
15	Haplotype and Phenotype Analysis of Nine Recurrent BRCA2 Mutations in 111 Families: Results of an International Study. American Journal of Human Genetics, 1998, 62, 1381-1388.	2.6	150
16	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	9.4	125
17	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	9.4	120
18	Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative forBRCA1 andBRCA2 alterations. Genes Chromosomes and Cancer, 2002, 33, 235-242.	1.5	106

#	Article	IF	Citations
19	Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Journal of Cancer, 1998, 34, 1922-1926.	1.3	105
20	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Human Mutation, 2019, 40, 1557-1578.	1.1	102
21	The Exon 13 Duplication in the BRCA1 Gene Is a Founder Mutation Present in Geographically Diverse Populations. American Journal of Human Genetics, 2000, 67, 207-212.	2.6	100
22	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2009, 18, 4442-4456.	1.4	99
23	Comparison of mRNA Splicing Assay Protocols across Multiple Laboratories: Recommendations for Best Practice in Standardized Clinical Testing. Clinical Chemistry, 2014, 60, 341-352.	1.5	95
24	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	5.8	93
25	Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer. PLoS Biology, 2011, 9, e1001199.	2.6	91
26	FANCMc.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. Human Molecular Genetics, 2015, 24, 5345-5355.	1.4	91
27	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	5.8	90
28	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	2.2	88
29	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	5.8	88
30	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	1.1	82
31	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers. Breast Cancer Research, 2012, 14, R33.	2.2	78
32	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2011, 13, R110.	2.2	71
33	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2011, 20, 3304-3321.	1.4	68
34	NM23 gene expression correlates with cell growth rate and S-phase. International Journal of Cancer, 1995, 60, 837-842.	2.3	66
35	Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis. International Journal of Cancer, 2006, 118, 1215-1226.	2.3	63
36	Microsatellite instability and mismatch repair gene inactivation in sporadic pancreatic and colon tumours. British Journal of Cancer, 1999, 80, 11-16.	2.9	60

#	Article	IF	Citations
37	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	2.2	57
38	A Novel Breast Cancerâ€“Associated BRIP1 (FANCJ/BACH1) Germ-line Mutation Impairs Protein Stability and Function. Clinical Cancer Research, 2008, 14, 4672-4680.	3.2	56
39	Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations. Journal of Medical Genetics, 2004, 41, 278-285.	1.5	55
40	Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. European Journal of Human Genetics, 2004, 12, 899-906.	1.4	55
41	Stimulation of carrot somatic embryogenesis by proline and serine. Plant Cell Reports, 1984, 3, 210-214.	2.8	54
42	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.4	54
43	BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: Novel mutations and unclassified variants. Gynecologic Oncology, 2012, 125, 687-692.	0.6	53
44	Thenm23 gene maps to human chromosome band 17q22 and shows a restriction fragment length polymorphism withbg/II. Genes Chromosomes and Cancer, 1992, 4, 84-88.	1.5	52
45	Cyclin D1 Overexpression in Thyroid Carcinomas: Relation with Clinico-Pathological Parameters, Retinoblastoma Gene Product, and Ki67 Labeling Index. Thyroid, 2000, 10, 741-746.	2.4	50
46	Down-regulation of thenm23.h1 gene inhibits cell proliferation. , 1997, 73, 297-302.		49
47	Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	3.4	48
48	The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. Clinical Cancer Research, 2011, 17, 3742-3750.	3.2	47
49	Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 645-657.	1.1	47
50	RNA-based analysis of BRCA1 and BRCA2 gene alterations. Cancer Genetics and Cytogenetics, 2006, 170, 93-101.	1.0	46
51	Usefulness of Technetium-99m Hexamethylpropylene Amine Oxime-Labeled Leukocyte Scintigraphy to Detect Pancreatic Necrosis in Patients with Acute Pancreatitis. Pancreatology, 2007, 7, 459-469.	0.5	46
52	Genetic alterations in hereditary breast cancer. Annals of Oncology, 2004, 15, i7-i13.	0.6	45
53	Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2011, 103, 105-116.	3.0	40
54	The CHEK2 c.1100delC mutation plays an irrelevant role in breast cancer predisposition in Italy. Human Mutation, 2004, 24, 100-101.	1.1	39

#	Article	IF	Citations
55	A yeast recombination assay to characterize humanBRCA1missense variants of unknown pathological significance. Human Mutation, 2009, 30, 123-133.	1.1	39
56	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.4	39
57	BRCA1 germline mutational spectrum in Italian families from Tuscany: a high frequency of novel mutations. Oncogene, 1996, 13, 1483-8.	2.6	37
58	Down regulation of NM23.H1, NM23.H2 and c-myc genes during differentiation induced by 1,25 dihydroxyvitamin D3. Leukemia Research, 1996, 20, 161-167.	0.4	36
59	High level of messenger RNA forBRMS1 in primary breast carcinomas is associated with poor prognosis. International Journal of Cancer, 2007, 120, 1169-1178.	2.3	35
60	PIK3CA in Breast Carcinoma. Diagnostic Molecular Pathology, 2009, 18, 200-205.	2.1	34
61	Ovarian cancer susceptibility alleles and risk of ovarian cancer inBRCA1andBRCA2mutation carriers. Human Mutation, 2012, 33, 690-702.	1.1	34
62	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Human Molecular Genetics, 2011, 20, 4732-4747.	1.4	32
63	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	0.6	32
64	PALB2: a novel inactivating mutation in a Italian breast cancer family. Familial Cancer, 2010, 9, 531-536.	0.9	30
65	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	3.0	30
66	Association between the BRCA2N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central Italy. BMC Cancer, 2007, 7, 170.	1.1	28
67	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	2.3	28
68	Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers. Breast Cancer Research and Treatment, 2007, 103, 29-36.	1.1	27
69	NM23 gene expression in human breast carcinomas: Loss of correlation with cell proliferation in the advanced phase of tumor progression. , 1997, 74, 102-111.		26
70	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	2.2	26
71	Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2mutation carriers. Breast Cancer Research, 2010, 12, R102.	2.2	25
72	Germline investigation in male breast cancer of DNA repair genes by next-generation sequencing. Breast Cancer Research and Treatment, 2019, 178, 557-564.	1.1	24

#	Article	IF	Citations
73	A low NM23.H1 gene expression identifying high malignancy human melanomas. Melanoma Research, 1994, 4, 179-184.	0.6	23
74	Ethical, Social and Economic Issues in Familial Breast Cancer: A Compilation of Views from the E.C. Biomed II Demonstration Project. Disease Markers, 1999, 15, 125-131.	0.6	23
75	Exploring the link between MORF4L1 and risk of breast cancer. Breast Cancer Research, 2011, 13, R40.	2.2	23
76	A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1362-1370.	1.1	23
77	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	1.4	23
78	Different Expressivity of BRCA1 and BRCA2: Analysis of 179 Italian Pedigrees with Identified Mutation. Breast Cancer Research and Treatment, 2003, 81, 71-79.	1.1	22
79	Reconstructing the Genealogy of a BRCA1 Founder Mutation by Phylogenetic Analysis. Annals of Human Genetics, 2008, 72, 310-318.	0.3	22
80	Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers. Breast Cancer Research, 2012, 14, R63.	2.2	22
81	Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling. Annals of Oncology, 2009, 20, 874-878.	0.6	21
82	Performance of BOADICEA and BRCAPRO genetic models and of empirical criteria based on cancer family history for predicting BRCA mutation carrier probabilities: A retrospective study in a sample of Italian cancer genetics clinics. Breast, 2013, 22, 1130-1135.	0.9	21
83	Lung Function Longitudinal Study by Phenotype and Genotype in Primary Ciliary Dyskinesia. Chest, 2020, 158, 117-120.	0.4	20
84	Identification of novel alternatively splicedBRCA1-associated RING domain (BARD1) messenger RNAs in human peripheral blood lymphocytes and in sporadic breast cancer tissues. Genes Chromosomes and Cancer, 2007, 46, 791-795.	1.5	19
85	Effect of the expression of BRCA2 on spontaneous homologous recombination and DNA damage-induced nuclear foci in Saccharomyces cerevisiae. Mutagenesis, 2013, 28, 187-195.	1.0	19
86	Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 232 for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group. JCO Precision Oncology, 2018, 2, 1-42.	1.5	19
87	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	2.9	19
88	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	5.8	19
89	Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	3.0	19
90	Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Human Genetics, 2011, 130, 685-699.	1.8	18

#	Article	IF	Citations
91	MSH2 role in BRCA1-driven tumorigenesis: A preliminary study in yeast and in human tumors from BRCA1-VUS carriers. European Journal of Medical Genetics, 2015, 58, 531-539.	0.7	18
92	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18
93	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	1.1	18
94	Functional Interaction Between BRCA1 and DNA Repair in Yeast May Uncover a Role of RAD50, RAD51, MRE11A, and MSH6 Somatic Variants in Cancer Development. Frontiers in Genetics, 2018, 9, 397.	1.1	18
95	Whole exome sequencing in familial isolated primary hyperparathyroidism. Journal of Endocrinological Investigation, 2020, 43, 231-245.	1.8	18
96	Haplotype analysis of BRCA1 gene reveals a new gene rearrangement: characterization of a 19.9 KBP deletion. European Journal of Human Genetics, 2004, 12, 775-777.	1.4	17
97	Mouse mammary tumor virus (MMTV) - like exogenous sequences are associated with sporadic but not hereditary human breast carcinoma. Aging, 2019, 11, 7236-7241.	1.4	17
98	Proline and serine affect polarity and development of carrot somatic embryos. Cell Differentiation, 1985, 17, 193-198.	1.3	16
99	p53 Inactivation is a Rare Event in Familial Breast Tumors Negative for BRCA1 and BRCA2 Mutations. Breast Cancer Research and Treatment, 2003, 82, 1-9.	1.1	16
100	Multimodal Assessment of Protein Functional Deficiency Supports Pathogenicity of BRCA1 p.V1688del. Cancer Research, 2009, 69, 7030-7037.	0.4	16
101	Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1032-1038.	1.1	16
102	Characterization of three alternative transcripts of the BRCA1 gene in patients with breast cancer and a family history of breast and/or ovarian cancer who tested negative for pathogenic mutations. International Journal of Molecular Medicine, 2015, 35, 950-956.	1.8	16
103	Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients. Genes Chromosomes and Cancer, 2016, 55, 915-924.	1.5	16
104	The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	1.1	16
105	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). British Journal of Cancer, 2009, 101, 2048-2054.	2.9	15
106	BRCA1 and BRCA2 5â€² noncoding region variants identified in breast cancer patients alter promoter activity and protein binding. Human Mutation, 2018, 39, 2025-2039.	1.1	15
107	PROMs in post-mastectomy care: Patient self-reports (BREAST-Qâ„¢) as a powerful instrument to personalize medical services. European Journal of Surgical Oncology, 2020, 46, 1034-1040.	0.5	15
108	Decreasing expression of NM23 gene in metastatic murine mammary tumors of viral etiology (MMTV). Anticancer Research, 1992, 12, 969-73.	0.5	15

#	Article	IF	Citations
109	Defective interleukin six expression and responsiveness in human mammary cells transformed by an adeno 5/SV40 hybrid virus. British Journal of Cancer, 1996, 73, 1356-1361.	2.9	14
110	Microsatellite alterations andp53, TGFÎ²RII, IGFIIR andBAX mutations in sporadic non-small-cell lung cancer. , 1998, 78, 606-609.		13
111	Insurance Implications for Individuals with a High Risk of Breast and Ovarian Cancer in Europe. Disease Markers, 1999, 15, 159-165.	0.6	13
112	Effect of the overexpression of BRCA2 unclassified missense variants on spontaneous homologous recombination in human cells. Breast Cancer Research and Treatment, 2011, 129, 1001-1009.	1.1	13
113	Microsatellite alterations and K-ras, TGFbetaRII, IGFRII and bax mutations in sporadic cancers of the gastrointestinal tract.. Oncology Reports, 2000, 7, 1371-5.	1.2	13
114	No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Breast Cancer Research and Treatment, 2009, 117, 371-379.	1.1	12
115	Identification of BRAF 3â€²UTR Isoforms in Melanoma. Journal of Investigative Dermatology, 2015, 135, 1694-1697.	0.3	12
116	Carcinosarcoma of the Breast: An Aggressive Subtype of Metaplastic Cancer. Report of a Rare Case in a Young BRCA-1 Mutated Woman. Clinical Breast Cancer, 2017, 17, e31-e35.	1.1	12
117	Next generation sequencing technologies for a successful diagnosis in a cold case of Leigh syndrome. BMC Neurology, 2018, 18, 99.	0.8	12
118	Effect of BRCA1 missense variants on gene reversion in DNA double-strand break repair mutants and cell cycle-arrested cells of Saccharomyces cerevisiae. Mutagenesis, 2020, 35, 189-195.	1.0	12
119	Longitudinal Lung Volume Changes by Ultrastructure and Genotype in Primary Ciliary Dyskinesia. Annals of the American Thoracic Society, 2021, 18, 963-970.	1.5	12
120	Origin of araC-induced endoreduplicated cells. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1987, 177, 261-265.	0.4	11
121	Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PLoS ONE, 2012, 7, e35706.	1.1	11
122	Disorders of sexual development with XY karyotype and female phenotype: clinical findings and genetic background in a cohort from a single centre. Journal of Endocrinological Investigation, 2021, 44, 145-151.	1.8	11
123	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	1.1	10
124	Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants. Genetics in Medicine, 2022, 24, 119-129.	1.1	10
125	Blepharophimosis, Ptosis, Epicanthus Inversus Syndrome: New Report with a 197-kb Deletion Upstream of FOXL2 and Review of the Literature. Molecular Syndromology, 2019, 10, 147-153.	0.3	9
126	Genomic PCR-SSCP analysis of the metastasis associated NM23-H1 (NME1) gene: a study on colorectal cancer. Anticancer Research, 1993, 13, 2149-54.	0.5	9

#	Article	IF	Citations
127	Increased rate of base substitution in a hamster mutator strain obtained during serial selection for gene amplification.. Molecular and Cellular Biology, 1990, 10, 6805-6808.	1.1	8
128	Risk Estimation as a Decision-Making Tool for Genetic Analysis of the Breast Cancer Susceptibility Genes. Disease Markers, 1999, 15, 53-65.	0.6	8
129	The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2012, 132, 1119-1126.	1.1	8
130	Expression of human poly (ADP-ribose) polymerase 1 in Saccharomyces cerevisiae: Effect on survival, homologous recombination and identification of genes involved in intracellular localization. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 774, 14-24.	0.4	8
131	Whole-exome analysis of a Liâ€“Fraumeni family trio with a novel TP53 PRD mutation and anticipation profile. Carcinogenesis, 2017, 38, 938-943.	1.3	8
132	Time course of sister chromatid exchanges and gene amplification induced by 1-?-d-arabinofuranosylcytosine in V79-AP4 Chinese hamster cells. Chromosoma, 1988, 96, 306-310.	1.0	7
133	Clinicopathological Significance of GADD45 Gene Alterations in Human Familial Breast Carcinoma. Breast Cancer Research and Treatment, 2004, 87, 197-201.	1.1	7
134	Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. British Journal of Cancer, 2011, 104, 1356-1361.	2.9	7
135	Association of SULT1A1 Arg213His polymorphism with male breast cancer risk: results from a multicenter study in Italy. Breast Cancer Research and Treatment, 2014, 148, 623-628.	1.1	7
136	Paternity in 5Î±-Reductase-2 Deficiency: Report of Two Brothers with Spontaneous or Assisted Fertility and Literature Review. Sexual Development, 2019, 13, 55-59.	1.1	7
137	Characterisation of gene expression profiles of yeast cells expressing BRCA1 missense variants. European Journal of Cancer, 2009, 45, 2187-2196.	1.3	6
138	A recombination-based method to characterize human BRCA1 missense variants. Breast Cancer Research and Treatment, 2011, 125, 265-272.	1.1	6
139	Detection of Germline Variants in 450 Breast/Ovarian Cancer Families with a Multi-Gene Panel Including Coding and Regulatory Regions. International Journal of Molecular Sciences, 2021, 22, 7693.	1.8	6
140	Accumulation of anchorage independent cells showing amplified genes (CAD) during the in vitro propagation of CHEF18 Chinese hamster cells. Cell Proliferation, 1993, 26, 161-170.	2.4	5
141	A region on the long arm of chromosome 16 is frequently deleted in metastatic node-negative breast cancer.. International Journal of Oncology, 1998, 13, 177-82.	1.4	5
142	Mutational Analysis of the NM23.H1 Gene in Human Breast Cancer. Cancer Genetics and Cytogenetics, 2000, 121, 181-185.	1.0	5
143	Choroid plexus carcinoma: a new case associated with a novel TP53 germ line mutation. Neuropathology and Applied Neurobiology, 2008, 34, 564-568.	1.8	5
144	Effects on human transcriptome of mutated BRCA1 BRCT domain: A microarray study. BMC Cancer, 2012, 12, 207.	1.1	5

#	Article	IF	Citations
145	Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup. Oncotarget, 2017, 8, 79188-79200.	0.8	5
146	NM23.H1 Loss of Heterozygpsity in Human Mammary Carcinomas.. Annals of the New York Academy of Sciences, 1993, 698, 136-142.	1.8	4
147	Genetic Testing for Breast Cancer Predisposition in 1999: Which Molecular Strategy and which Family Criteria?. Disease Markers, 1999, 15, 67-68.	0.6	4
148	Feline immunodeficiency virus vector as a tool for preventative strategies against human breast cancer. Veterinary Immunology and Immunopathology, 2010, 134, 132-137.	0.5	4
149	Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2012, 136, 295-302.	1.1	4
150	Identification of two novel BRCA1-partner genes in the DNA double-strand break repair pathway. Breast Cancer Research and Treatment, 2013, 141, 515-522.	1.1	4
151	Nutrition, epigenetic markers and growth in preterm infants. Journal of Maternal-Fetal and Neonatal Medicine, 2021, 34, 3963-3968.	0.7	4
152	Disorders/Differences of Sex Development Presenting in the Newborn With 46,XY Karyotype. Frontiers in Pediatrics, 2021, 9, 627281.	0.9	3
153	Increased rate of base substitution in a hamster mutator strain obtained during serial selection for gene amplification. Molecular and Cellular Biology, 1990, 10, 6805-6808.	1.1	3
154	Validation and Data-Integration of Yeast-Based Assays for Functional Classification of BRCA1 Missense Variants. International Journal of Molecular Sciences, 2022, 23, 4049.	1.8	3
155	Mutation Analysis of BRCA1 and BRCA2 in Italian Hereditary and Sporadic Forms of Breast and Ovarian Cancers: Tumor Genotype-Phenotype Correlation in Breast Cancer BRCA-Mutation Carriers. Disease Markers, 1999, 15, 101-102.	0.6	1
156	Reply to BRCA2 splice site mutations in an Italian breast/ovarian cancer family. Annals of Oncology, 2009, 20, 1285-1286.	0.6	0
157	BRCA1 gene variant p.P142H associated with male breast cancer: a two-generation genealogic study and literature review. Familial Cancer, 2015, 14, 515-519.	0.9	0
158	Abstract 1859: Bioinformatic and experimental evaluation of regulatory variants in breast cancer susceptibility genes. , 2016, , .		0